Form 4: ATAI Life Sciences Director John Hoffman Granted 206,000 Stock Options

ATAI Life Sciences N.V. Director John Francis Hoffman was granted 206,000 stock options with an exercise price of $2.25, vesting over three years.

Summary

• John Francis Hoffman, a Director of ATAI Life Sciences N.V. (ATAI), was granted 206,000 stock options.
• The stock options have an exercise price of $2.25 per common share.
• The earliest transaction date for this grant was June 26, 2025.
• The options will vest in stages: one-third of the underlying shares on June 26, 2026, and the remaining shares in twenty-four substantially equal monthly installments thereafter.
• The stock options will become fully vested on June 26, 2028.
• The expiration date for these stock options is June 26, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of aligning management's interests with long-term shareholder value, though it does not directly reflect operational performance or financial results.

Positives

• The grant of 206,000 stock options to Director John Francis Hoffman aligns his interests with long-term shareholder value.
• The multi-year vesting schedule encourages sustained commitment and performance from the director.

Future Outlook

This filing details a future vesting schedule for stock options granted to a director, aligning his future compensation with the company's stock performance and long-term strategic goals.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align management interests with shareholder value. This is a standard compensation mechanism for board members in growth-oriented companies like ATAI Life Sciences.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in the biotechnology sector, to align executive and board interests with shareholder value.
• While specific grant sizes vary based on company size, stage, and individual roles, the use of performance-based equity awards like stock options with multi-year vesting schedules is a widely accepted benchmark for executive and director compensation.

Related Party Transactions

• Grant of 206,000 stock options to John Francis Hoffman, a Director of ATAI Life Sciences N.V., with an exercise price of $2.25 per share. This constitutes a related party transaction as it involves a company director.

Stakeholder Impact

• Shareholders: Potential future dilution if the options are exercised, but also improved alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The stock options will begin vesting on June 26, 2026.
• The stock options will continue to vest monthly until fully vested on June 26, 2028.
• The director may exercise the vested options at any time before the expiration date of June 26, 2035.

Key Dates

Keywords

ATAI Life Sciences, stock options, director compensation, SEC Form 4, beneficial ownership, equity grant, insider transaction